Aldo-keto reductase's mechanism in brain injury from hypoxia-ischemia and tetrahydrobiopterin deficiency

Active Grant Awarded

Award ID
R01NS146896
Recipient
Awarding agency
Obligated
$625,792

Award facts

Completion date 4% complete
Place of performance
Wauwatosa, WI 53226, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services, National Institutes of Health, National Institute of Neurological Disorders and Stroke awarded The Medical College of Wisconsin, Inc. a $625,792 grant on September 9, 2026, under Assistance Listing 93.853, Extramural Research Programs in the Neurosciences and Neurological Disorders. The program supports extramural NINDS research into the fundamental structure and function of the brain and nervous system and the reduction of neurological disease burden.

The funded project tests whether aldo-keto reductase (AKR) enzymes, which regulate expression through the transcription factor NRF2, can be harnessed in the brain to mitigate tetrahydrobiopterin (BH4) and neurotransmitter deficiencies. The stated aims are to evaluate the therapeutic potential of AKRs and to elucidate the mechanisms regulating BH4 synthesis in the brain, including establishing AKR relevance to cell function. The recipient's prior work showed that antenatal hypoxia-ischemia depletes BH4 and causes hypertonia. The project uses transgenic SPR-knockout rabbits, which display motor deficits at birth and lack hyperphenylalaninemia, as a preclinical model. The source identifies the work as the first to define AKR roles in a preclinical rabbit model.

The period of performance runs through July 31, 2031, and the place of performance is Wauwatosa, WI 53226. The source describes no sub-recipients for this award.

Description

Abstract
Congenital tetrahydrobiopterin (BH4) deficiency causes motor and behavioral impairments and irreversible intellectual disabilities. Currently, no definitive therapies exist to effectively restore BH4 levels in the human brain, and clinical management is largely limited to correcting dopamine and serotonin deficiencies. Hyperphenylalaninemia (HPA) is a common manifestation of BH4 deficits, except in cases resulting from pathogenic variants in sepiapterin reductase (SPR), a key enzyme in BH4 synthesis. This exception is believed to reflect compensatory activity of aldo-keto reductase (AKR) enzymes, which are abundant in the liver and can substitute for SPR to sustain BH4 production. However, the role of akrs in the brain remains poorly understood. If AKR activity in the brain can be harnessed, IT may offer a novel neuroprotective strategy to boost BH4 levels. Notably, AKR expression is regulated by the transcription factor NRF2. The primary goal of this proposal is to evaluate the therapeutic potential of akrs and elucidate the mechanisms regulating BH4 synthesis in the brain. We hypothesize that specific akrs can mitigate BH4 and neurotransmitter deficiencies, thereby improving neuronal and motor function. Our prior work demonstrates that antenatal hypoxia-ischemia (H-I) causes BH4 depletion and hypertonia. To further investigate the link between BH4 loss and motor dysfunction, we have generated transgenic SPR-knockout (SPR-KO) rabbits, a powerful toolkit for developmental neuroscience. These animals display motor deficits at birth, providing distinct advantages over mouse models, including spontaneous motor impairments and the absence of HPA. This study will be the first to define the role of akrs in a preclinical rabbit model. To establish the relevance of AKR in improving cell function, we aim to 1) determine whether AKR induction enhances BH4 synthesis in neuronal cells to levels meeting or exceeding the physiological threshold, using AKR knock-in and crispr/CAS9-engineered SPR-KO cell lines lacking alternative reductases. Additionally, we will 2) investigate whether pharmacological AKR activation stabilizes tyrosine hydroxylase and improves dopamine production in neuronal cells from distinct brain regions of SPR-KO rabbits, identifying optimal dosing and timing to inform in vivo studies. Importantly, we will assess whether AKR- mediated BH4 synthesis triggers region-specific responses in the brain, ultimately ameliorating motor function. Finally, we will examine wild-type and SPR-KO fetal rabbits and inducers of AKR to 3) determine whether AKR- mediated BH4 synthesis reduces H-I-induced hypertonia and define the underlying mechanisms by comparing hypertonic and non-hypertonic animals. By integrating molecular, cellular, and behavioral approaches, this project seeks to establish akrs as a novel therapeutic target for BH4-related neurological disorders and lay the groundwork for innovative strategies to enhance neuroprotection and motor function.

Quick answers

Who received award R01NS146896?

R01NS146896 was awarded to The Medical College Of Wisconsin, Inc. by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on September 9, 2026.

How much is award R01NS146896 worth?

$625,792 has been obligated on R01NS146896.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award